dc.creatorConrad, Karsten
dc.creatorRoeber, Nadja
dc.creatorAndrade, Luis E. C. [UNIFESP]
dc.creatorMahler, Michael
dc.date.accessioned2020-07-17T14:02:33Z
dc.date.accessioned2022-10-07T21:00:24Z
dc.date.available2020-07-17T14:02:33Z
dc.date.available2022-10-07T21:00:24Z
dc.date.created2020-07-17T14:02:33Z
dc.date.issued2017
dc.identifierClinical Reviews In Allergy & Immunology. Totowa, v. 52, n. 2, p. 202-216, 2017.
dc.identifier1080-0549
dc.identifierhttps://repositorio.unifesp.br/handle/11600/54860
dc.identifier10.1007/s12016-016-8564-5
dc.identifierWOS:000397573000005
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4025941
dc.description.abstractDespite all the progress in the establishment of specific autoantibody assays, screening for antinuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells for quality-oriented laboratory diagnosis of ANA associated rheumatic diseases (AARD) remains indispensable but is not without limitations. Recent data on the relevance of the dense fine speckled (DFS) pattern and anti-DFS70 antibodies disclosed novel possibilities to optimize the serological stepwise diagnostics of AARD. The DFS pattern on HEp-2 cells is well differentiated from the classic "homogeneous" ANA pattern associated with dsDNA antibodies. This is the most frequent pattern in high titer ANA-positive healthy persons. The most characteristic ANA specificity associated with DFS pattern is the anti-DFS70 antibody (synonym LEDGF antibody). The prevalence of anti-DFS70 antibodies in AARD patients is significantly lower compared with the prevalence in ANA-positive healthy persons. There is a negative association between anti-DFS70 antibodies and AARD, especially if no concomitant AARD-specific autoantibodies are found. Isolated anti-DFS70 antibodies are detectable in less than 1 % of AARD but are detectable in 2-22 % of healthy persons. In the presence of an isolated anti-DFS70 antibody, the posttest probability for AARD is reduced significantly. The significance of anti-DFS70 antibodies as a criterion that helps to exclude AARD is also confirmed by follow-up studies on anti-DFS70 antibodies of positive, healthy individuals, who did not develop any AARD during a 4 year observation period. Consequently, anti-DFS70 antibodies are valuable novel biomarkers for better interpretation of positive ANA in cases of negative AARD-associated autoantibodies and should be integrated in modified test algorithms to avoid unnecessary referrals and examinations of ANA-positive persons.
dc.languageeng
dc.publisherHumana Press Inc
dc.relationClinical Reviews In Allergy & Immunology
dc.rightsAcesso restrito
dc.subjectAntinuclear antibodies
dc.subjectAnti-DFS70 antibodies
dc.subjectANA-associated rheumatic diseases
dc.subjectDiagnostics
dc.titleThe Clinical Relevance of Anti-DFS70 Autoantibodies
dc.typeArtigo


Este ítem pertenece a la siguiente institución